Explore 3 Stock Ideas & Industry Insights Download Free Report

Stocks

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

– Generated Q1’25 Quarterly Net Revenue of $177.8 Million,Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – …

EODHD | 08 May 2025

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025

1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to Report Updated Clinical Data for …

EODHD | 08 May 2025

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Phase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients Updated JANX007 data from Phase 1a dose escalation support initiation of Phase 1b dose expansion Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the second half of 2025 …

EODHD | 08 May 2025

Research Frontiers Reports First Quarter 2025 Financial Results and Will Host a Conference Call at 4:30p.m. Today

WOODBURY, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its first quarter of 2025. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and operating results as well …

EODHD | 08 May 2025

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that it has …

EODHD | 08 May 2025

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity modelIn vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus …

EODHD | 08 May 2025

Teknova Reports First Quarter 2025 Financial Results

First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” …

EODHD | 08 May 2025

The Trade Desk Reports First Quarter 2025 Financial Results

LOS ANGELES, May 08, 2025--(BUSINESS WIRE)--The Trade Desk, Inc. ("The Trade Desk," the "Company" or "we") (NASDAQ: TTD), a provider of a global technology platform for buyers of advertising, today announced financial results for its first quarter ended March 31, 2025. "We delivered strong …

EODHD | 08 May 2025

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and …

EODHD | 08 May 2025

Serve Robotics Announces First Quarter 2025 Results

Successfully built and deployed 250 new third-generation robots, enhancing operational scale and efficiency Continued geographic expansion into Miami and Dallas metros; Atlanta launch on track First quarter revenue of $440 thousand, a 150% increase versus Q4 2024 Unlocking the value of Serve’s software and …

EODHD | 08 May 2025
Support

Hi! How can we help you today?

Loading…